Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$5.41 USD
-0.03 (-0.55%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $5.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 81 - 100 ( 441 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2022 Roundup for Covered Companies (Part 2)
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22: Early-Stage Trials Continue. How Pivotal Trials Will Be Run Is Key
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR 2022 Abstract Roundup For Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2021 Financials; Multiple Datasets Slated for 2022; Modulating PT to $115
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q21: Initiation of a Pivotal Study Slated for Year-End 2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T